KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Net Cash Flow (2018 - 2025)

Vir Biotechnology's Net Cash Flow history spans 8 years, with the latest figure at $61.8 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 13.7% year-over-year to $61.8 million; the TTM value through Dec 2025 reached -$77.6 million, down 235.23%, while the annual FY2025 figure was -$77.6 million, 235.23% down from the prior year.
  • Net Cash Flow for Q4 2025 was $61.8 million at Vir Biotechnology, up from -$127.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $690.9 million in Q2 2022 and bottomed at -$542.7 million in Q3 2022.
  • The 5-year median for Net Cash Flow is -$40.6 million (2021), against an average of -$10.5 million.
  • The largest YoY upside for Net Cash Flow was 452.44% in 2022 against a maximum downside of 1816.04% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at -$364.2 million in 2021, then skyrocketed by 68.15% to -$116.0 million in 2022, then tumbled by 81.95% to -$211.1 million in 2023, then surged by 125.76% to $54.4 million in 2024, then grew by 13.7% to $61.8 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Net Cash Flow are $61.8 million (Q4 2025), -$127.0 million (Q3 2025), and -$61.7 million (Q2 2025).